Earlier this month, Pfizer announced promising first-line results from a Phase 2b/3 trial testing the JAK inhibitor ritecitinib for the treatment of alopecia(baldness), suggesting that the drug could finally be approved to treat this autoimmune disease that causes hair loss.
Our Analysis:
As long as the price is above 44.80, follow the recommendations below:
- Time frame: D1
- Recommendation: long position
- Entry point: 47.24
- Take Profit 1: 49.80
- Take Profit 2: 51.00
Alternative scenario:
If the level of 44.80 is broken-down, follow the recommendations below:
- Time frame: D1
- Recommendation: short position
- Entry point: 44.80
- Take Profit 1: 42.80
- Take Profit 2: 41.60
No comments:
Post a Comment